Onco Wiki / Doença

Tumor neuroendocrino pancreático (pNET), bem diferenciado G1/G2

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDDIS-PNET
TipoDoença
Alegais
PNET funcional (insulinoma, gastrinoma, glucagonoma, VIPoma)Non-functional pNETTumor de células de islote pancreáticasTumor neuroendocrino pancreáticoPNETНейроендокринна пухлина підшлункової залози (пНЕП), добре-диференційована G1/G2
Estadoreviewed 2026-05-03 | pending_clinical_signoff
DoençasNenhuma declaração
FontesSRC-NCCN-NET-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fonte YAML

icd_o_3_morphology8240/3
icd_o_3_topography["C25"]
icd_10C25.4
who_classificationWHO Classification of Digestive System Tumours 5th ed (2019): Pancreatic neuroendocrine tumour G1 (Ki67 <3%), G2 (3–20%), G3 (>20% but well-differentiated)

Capacidades

Notas

Well-differentiated pNET G1/G2 is the dominant subtype in clinical practice (non-functional, discovered incidentally or via abdominal mass/liver mets). Grading per WHO 2019: G1 Ki67 <3%, G2 Ki67 3–20%. G3 well-differentiated pNET (Ki67 >20%) occupies a grey zone — still well-differentiated morphologically but higher proliferation; NCCN recommends everolimus/sunitinib/SSA ± chemo; not modelled separately here (flagged via RF-NET-HIGH-GRADE-G3 for MDT review). Distinguishing from poorly differentiated NEC (ICD-O 8246/3) is essential: NEC requires platinum-etoposide chemotherapy (not SSA/TKI/mTOR). Key trials: RADIANT-3 (everolimus, Yao NEJM 2011), Raymond 2011 (sunitinib), CLARINET pNET subgroup (lanreotide). Surgery remains the only curative option for localized disease.

Usado por

Relevância terapêutica

Algoritmos

Doença

Indicação

Procedimentos

Questionários

Sinal de alerta

Fontes